Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001062993-25-006767
Filing Date
2025-04-01
Accepted
2025-04-01 21:49:04
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10894
2 EXHIBIT 2 exhibit2.htm EX-2 11742
  Complete submission text file 0001062993-25-006767.txt   24491
Mailing Address 1900 MARKET STREET SUITE 200 PHILADELPHIA PA 19103
Business Address 1900 MARKET STREET SUITE 200 PHILADELPHIA PA 19103 6177728515
abrdn Life Sciences Investors (Subject) CIK: 0000884121 (see all company filings)

EIN.: 043147016 | State of Incorp.: MA | Fiscal Year End: 0930
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-48561 | Film No.: 25801811

Mailing Address 405 LEXINGTON AVENUE 58TH FLOOR NEW YORK NY 10174
Business Address 405 LEXINGTON AVENUE 58TH FLOOR NEW YORK NY 10174 212-542-4635
Saba Capital Management, L.P. (Filed by) CIK: 0001510281 (see all company filings)

EIN.: 800361690 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A